4D Molecular Therapeutics Ownership | Who Owns 4D Molecular Therapeutics?

Overview Forecast RevenueFinancials Chart

4D Molecular Therapeutics Ownership Summary

4D Molecular Therapeutics is owned by 9.96% institutional investors, 3.62% insiders, and 86.42% retail investors. Blackrock is the largest institutional shareholder, holding 9.94% of FDMT shares. Vanguard US Total Market Shares ETF is the top mutual fund, with 3.32% of its assets in 4D Molecular Therapeutics shares.

FDMT Ownership Benchmark

Type	Name	% Inst	% Insiders	% Retail
Stock	4D Molecular Therapeutics	9.96%	3.62%	86.42%
Sector	Healthcare Stocks	232.51%	10.72%	-143.22%
Industry	Biotech Stocks	384.55%	10.58%	-295.13%

Institutional Shareholders

Top Institutional Shareholders by Total Shares

Holder	Shares	% Holding	Value
Blackrock	4.90M	9.94%	$102.79M
Bvf inc/il	4.63M	8.28%	$40.23M
Ra capital management	4.56M	8.16%	$39.65M
Goldman sachs group	4.30M	7.67%	$32.27M
Blackrock funding, inc. /de	4.06M	7.24%	$30.49M
Vanguard group	3.09M	5.51%	$23.20M
Janus henderson group	2.25M	4.05%	$12.54M
Novo	2.00M	3.58%	$17.38M
Federated hermes	1.61M	2.87%	$12.07M
Millennium management	1.42M	2.56%	$7.91M

Top Institutional Shareholders by % of Total Assets

Holder	Shares	% Assets	Value
Peapod lane capital	268.02K	1.71%	$2.01M
Bvf inc/il	4.63M	1.63%	$40.23M
Novo	2.00M	1.12%	$17.38M
Ra capital management	4.56M	0.49%	$39.65M
Rangeley capital	42.66K	0.32%	$370.76K
Privium fund management b.v.	210.00K	0.29%	$1.57M
Principia wealth advisory	53.67K	0.25%	$402.51K
Parkman healthcare partners	200.00K	0.18%	$1.74M
Armistice capital	1.10M	0.14%	$9.52M
Silverarc capital management	100.00K	0.10%	$750.00K

Top Buyers

Holder	Shares	% Assets	Change
Millennium management	1.42M	0.00%	1.34M
Armistice capital	1.10M	0.14%	796.00K
Blackrock	4.90M	0.00%	612.35K
Vanguard group	3.09M	0.00%	518.40K
Norges bank	500.82K	0.00%	500.82K

Top Sellers

Holder	Shares	% Assets	Change
Viking global investors lp	-	-	-2.93M
Braidwell lp	-	-	-1.23M
Casdin capital	-	-	-1.15M
Janus henderson group	2.25M	0.01%	-884.85K
Polar capital	-	-	-838.49K

New Positions

Holder	Shares	% Assets	Change	Value
Norges bank	500.82K	0.00%	500.82K	$2.79M
Parkman healthcare partners	200.00K	0.18%	200.00K	$1.74M
Schonfeld strategic advisors	179.07K	0.01%	179.07K	$1.56M
Adage capital partners gp	175.00K	0.00%	175.00K	$1.52M
Hudson bay capital management lp	113.30K	0.01%	113.30K	$2.38M

Sold Out

Holder	Change
Northwestern mutual wealth management	-1.00
Innealta capital	-4.00
Nelson, van denburg & campbell wealth management group	-8.00
Allspring global investments	-27.00
Rothschild investment	-35.00

Institutional Ownership Trends

Date	Holdings	Change %	Shares	Change %	Ownership	Change %	Increased Position	Change %	Decreased Position	Change %
Dec 31, 2025	40	-70.59%	5,592,450	-85.86%	9	0.20%	21	-69.12%	10	-77.78%
Sep 30, 2025	39	-65.49%	6,758,953	-80.69%	12	0.31%	21	-62.50%	11	-69.44%
Jun 30, 2025	120	-4.00%	40,390,122	-6.26%	72	1.21%	58	23.40%	39	-35.00%
Mar 31, 2025	125	-14.38%	43,088,441	-8.05%	77	1.09%	47	-43.37%	60	36.36%
Dec 31, 2024	144	2.86%	46,861,479	-18.79%	84	0.78%	82	9.33%	44	2.33%

Top Mutual Funds Shareholders

Holder	Shares	% Holding	Change
Vanguard US Total Market Shares ETF	1.54M	3.32%	-
Vanguard Total Stock Mkt Idx Inv	1.50M	3.22%	-33.14K
Federated Hermes MDT Small Cap Core IS	1.12M	2.42%	253.62K
Federated Hermes MDT SCC Institutional	1.12M	2.42%	253.62K
iShares Russell 2000 ETF	1.00M	2.14%	-
SPDR® S&P Biotech ETF	986.40K	2.13%	14.03K
Janus Henderson Global Life Sciences	835.18K	1.80%	-116.90K
Janus Henderson Global Life Sciences D	835.18K	1.79%	-3.02K
Janus Global Life Science AUSD	717.92K	1.55%	-20.50K
Janus Henderson Glb Life Scn I2 USD	711.63K	1.52%	-4.41K

Recent Insider Transactions

Date	Name	Role	Activity	Value
Dec 20, 2025	Gupta Ashoo	VP, Finance and Controller	Sell	$685.72
Dec 20, 2025	Gupta Ashoo	VP, Finance and Controller	Sell	$2.69K
Dec 16, 2025	Bizily Scott	Chief Legal Officer	Sell	$17.82K
Nov 17, 2025	Bizily Scott	Chief Legal Officer	Sell	$17.31K
Oct 24, 2025	Bizily Scott	Chief Legal Officer	Sell	$32.14K

Insider Transactions Trends

Date	Buy	Sell
2026 Q1	-	-
2025 Q4	-	7
2025 Q3	-	1
2025 Q2	-	-
2025 Q1	-	-

FDMT Ownership FAQ

Who Owns 4D Molecular Therapeutics?

4D Molecular Therapeutics shareholders are primarily institutional investors at 9.96%, followed by 3.62% insiders and 86.42% retail investors. The average institutional ownership in 4D Molecular Therapeutics's industry, Biotech Stocks , is 384.55%, which 4D Molecular Therapeutics falls below.

Who owns the most shares of 4D Molecular Therapeutics?

4D Molecular Therapeutics’s largest shareholders are Blackrock (4.9M shares, 9.94%), Bvf inc/il (4.63M shares, 8.28%), and Ra capital management (4.56M shares, 8.16%). Together, they hold 26.38% of 4D Molecular Therapeutics’s total shares outstanding.

Does Blackrock own 4D Molecular Therapeutics?

Yes, BlackRock owns 9.94% of 4D Molecular Therapeutics, totaling 4.9M shares as of Jun 2024. This represents 0.00% of BlackRock's total assets, with a market value of 102.79M$. In the last quarter, BlackRock increased its holdings by 612.35K shares, a 14.29% change.

Who is 4D Molecular Therapeutics’s biggest shareholder by percentage of total assets invested?

Peapod lane capital is 4D Molecular Therapeutics’s biggest shareholder by percentage of total assets invested, with 1.71% of its assets in 268.02K 4D Molecular Therapeutics shares, valued at 2.01M$.

Who is the top mutual fund holder of 4D Molecular Therapeutics shares?

Vanguard US Total Market Shares ETF is the top mutual fund holder of 4D Molecular Therapeutics shares, with 3.32% of its total shares outstanding invested in 1.54M 4D Molecular Therapeutics shares.

Try Tickergate Pro Free

Customize Everything. 100% Flexibility. Fast and Easy to Use (No code or Excel Needed)

Customize your own personal stocks lists, views and charts
Choose from hundreds of fields, up to 15 years of history
Conduct deep comparison analysis

Discover trending investment themes
Find your next best investment
Research stocks using tools